Medicine:叶酸补充剂可显著降低CVD患者卒中的发生风险

2019-10-20 不详 网络

既往研究探究了叶酸补充剂在降低患者卒中发生风险中的有效性,但是,可获得的结果尚无定论且相互矛盾。该系统评价和荟萃分析旨在评估叶酸在心血管疾病(CVD)患者中的作用。搜索PubMed,EMBASE和Cochrane库数据库,收集相关文献进行了荟萃分析以评估补充叶酸在CVD患者中的作用。总结全因死亡率,心血管疾病死亡率,冠心病(CHD)和卒中的风险;计算危险比(HR),相对风险(RR)及其95%置信区

既往研究探究了叶酸补充剂在降低患者卒中发生风险中的有效性,但是,可获得的结果尚无定论且相互矛盾。该系统评价和荟萃分析旨在评估叶酸在心血管疾病(CVD)患者中的作用。

搜索PubMed,EMBASE和Cochrane库数据库,收集相关文献进行了荟萃分析以评估补充叶酸在CVD患者中的作用。总结全因死亡率,心血管疾病死亡率,冠心病(CHD)和卒中的风险;计算危险比(HR),相对风险(RR)及其95%置信区间(CI)。使用固定效果模型汇总分析数据。共有12项随机对照试验,包括47,523名参与者,符合本系统评价和荟萃分析的纳入标准。

结果显示,与接受对照治疗的患者相比,接受叶酸治疗的心血管疾病患者的卒中风险显著降低(RR = 0.85,95%CI = 0.77-0.94,异质性 = .347,I = 10.6%)。然而,两组患者在全因死亡率(HR,0.97,95%CI,0.86-1.10,异质性= .315,I = 15.4%),心血管疾病死亡率(HR,0.87,95%CI,0.66-1.15,异质性= .567,I = 0)和CHD风险(RR,1.04,95%CI,0.99-1.10,异质性= .725,I = 0)方面无明显差异。

综上所述,这项荟萃分析表明,补充叶酸可显著降低CVD患者卒中的发生风险。

原始出处:

Wang Y, Jin Y, et al., The effect of folic acid in patients with cardiovascular disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Sep;98(37):e17095. doi: 10.1097/MD.0000000000017095.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2020-06-09 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2020-04-16 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2019-10-22 heli0118
  6. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2019-10-21 14758c02m67暂无昵称

    文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2019-10-21 天地飞扬

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2019-10-20 一个字-牛

    学习了谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1634729, encodeId=01371634e2909, content=<a href='/topic/show?id=752938e10b2' target=_blank style='color:#2F92EE;'>#叶酸补充剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38710, encryptionId=752938e10b2, topicName=叶酸补充剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091122265773, createdName=Tamikia, createdTime=Fri Jul 31 02:18:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858996, encodeId=8c081858996ff, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jun 09 14:18:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773818, encodeId=be121e738184d, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Apr 16 02:18:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577690, encodeId=281215e769082, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610041, encodeId=866b161004198, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Oct 22 10:18:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374184, encodeId=4aca3e4184a4, content=文章里没有说能降低CVD患者叶酸的用量,叶酸对已经发生过卒中的患者是否也有降低再发卒中的功效,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Mon Oct 21 16:06:06 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374178, encodeId=b17e3e41783f, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 21 11:59:48 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374158, encodeId=40423e4158ca, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Oct 20 22:29:36 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026478, encodeId=312b10264e8b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Oct 20 22:18:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2019-10-20 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0